NovaBridge Biosciences

Aug 13, 2026

▲ +2.1%today

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

NovaBridge Biosciences will hold a webcast on August 20, 2026, to discuss its financial results for the first half of the year and recent corporate developments. The company focuses on innovative therapies in oncology and ophthalmology, with programs like givastomig and VIS-101. The webcast will be accessible live and archived for later viewing.

Jul 24, 2026

NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026

NovaBridge Biosciences has announced its annual general meeting (AGM) scheduled for September 8, 2026, in Shanghai. Shareholders of record by July 27, 2026, are entitled to attend and vote. The company has also filed its annual report with the SEC, detailing its financial performance and ongoing clinical developments.

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO, effective July 1, 2026. Dr. Gupta, who has over two decades of leadership experience, aims to advance the company's drug candidates, including givastomig and VIS-101. She succeeds Xi-Yong Fu, who will remain in an advisory role during the transition.

Jun 16, 2026

NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

NovaBridge Biosciences has received FDA Fast Track Designation for its drug givastomig, aimed at treating first-line HER2-negative metastatic gastric cancer. The designation is based on positive Phase 1b trial results demonstrating efficacy and tolerability. The company plans to initiate a registrational Phase 3 trial as early as Q4 2026, with detailed data presentation expected in late 2026.

May 28, 2026

NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference

NovaBridge Biosciences will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The company's presentation will include updates on its innovative pipeline, including givastomig and VIS-101. Givastomig is currently in a Phase 2 study for gastric cancer, while VIS-101 is expected to enter a Phase 2b study for retinal diseases. The webcast will be available for 90 days post-conference.

May 12, 2026

NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

NovaBridge Biosciences will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is advancing its innovative pipeline, including givastomig for gastric cancer and VIS-101 for retinal diseases. Positive results from previous studies bolster its prospects. The presentation will be available via webcast for 90 days.

Apr 22, 2026

NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

NovaBridge Biosciences has appointed Mark Hagler as President and Chief Commercial Officer to enhance its commercial strategy. Hagler brings over 25 years of experience in biopharmaceuticals, particularly in oncology and ophthalmology. His leadership is expected to drive the advancement of NovaBridge's pipeline, including the potential first-in-class drug givastomig for gastric cancer.

Apr 8, 2026

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

NovaBridge Biosciences reported its financial results for 2025, highlighting significant progress in its pipeline, particularly for givastomig and VIS-101. The company noted promising data supporting both candidates, with givastomig potentially eligible for an Accelerated Approval pathway. Despite a rise in net losses and R&D expenses, NovaBridge remains committed to advancing its innovative therapies.

Mar 16, 2026

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer • FDA confirmed givastomig's potential eligibility for an accelerated approval pathway

NovaBridge announced a productive Type B meeting with the FDA, confirming the eligibility of its drug givastomig for an accelerated approval pathway in gastric cancer. The company intends to begin a Phase 3 trial combining givastomig with immunochemotherapy as early as Q4 2026, based on promising Phase 1b trial results showing a 75% objective response rate. Givastomig is being positioned as a first-in-class therapy for patients with specific tumor characteristics in gastroesophageal cancer. Detailed trial designs will be discussed in further meetings with the FDA.

Mar 9, 2026

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

NovaBridge Biosciences and its subsidiary Visara have announced positive topline results from the Phase 2a study of VIS-101, a dual VEGF-A X ANG-2 inhibitor for wet AMD. The study showed rapid and durable treatment responses, with a favorable safety profile. Plans are underway to initiate a Phase 2b study later this year, followed by a global Phase 3 program in 2027.

NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

NovaBridge Biosciences will host a virtual business update call on March 9, 2026, to discuss Phase 2a clinical data for VIS-101, a dual VEGF-A/ANG-2 inhibitor targeting wet AMD. The drug aims to offer more effective and durable treatment compared to current standards. Visara, a subsidiary of NovaBridge, holds global rights to VIS-101 outside Greater China.

Mar 2, 2026

▲ +5.2%on this newsshared move

NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

NovaBridge Biosciences will present at the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026. The company's management will participate in a fireside chat on March 11 at 8:00 AM ET. NovaBridge focuses on innovative medicines, with key products including givastomig and VIS-101, both in advanced clinical stages.

Feb 25, 2026

Company Presentation February 2026 Disclaimer This presentation has been prepared by NovaBridge Biosciences (the “Company”) solely for informational purposes. Certain of the information included herein was

NovaBridge Biosciences has outlined its business strategy and pipeline in a presentation for February 2026. The company is focused on bridging Asian biotechnology innovations to global markets with a diverse asset portfolio. It emphasizes a hub-and-spoke model to facilitate accelerated development and commercialization of its drug candidates across various therapeutic areas. However, the presentation also cautions about the risks associated with forward-looking statements and the need for verifiable clinical results.

Feb 19, 2026

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform • Appointment is a positive endorsement of NovaBridge's uniqu

NovaBridge Biosciences has appointed Dr. Emmett T. Cunningham as the new Vice Chairman of its Board of Directors. With extensive experience in biopharma and a proven track record, Dr. Cunningham aims to drive shareholder value and foster innovation within the company. He will also join the Board's Research and Development Committee, focusing on expediting the development of transformative medicines. This appointment is viewed positively as part of NovaBridge's strategic efforts to advance its unique biotech platform and enhance access to crucial therapies.

Feb 18, 2026

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

NovaBridge Biosciences has initiated a global Phase 2 study for givastomig, a bispecific antibody targeting Claudin 18.2, in combination with nivolumab and chemotherapy for patients with 1L metastatic gastric cancer. This follows positive Phase 1b results indicating strong efficacy and safety. The study aims to confirm these findings and validate givastomig's potential as a leading therapy in this indication.

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei

NovaBridge Biosciences announced that Executive Chairman Fu Wei intends to purchase up to $5 million of the company's ADSs in open market transactions, which commenced on January 15, 2026. This move reflects confidence in the company's future, especially following positive Phase 1b data for givastomig in treating metastatic gastric cancer. NovaBridge emphasizes its commitment to innovative medicine and growth potential.

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer • Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show

NovaBridge has reported positive outcomes from its Phase 1b study of givastomig, a bispecific antibody in combination with nivolumab and mFOLFOX6 for treating HER2-negative metastatic gastric cancer. The study demonstrated an overall response rate (ORR) of 77% at the 8 mg/kg dose. Median progression-free survival (PFS) was recorded at 16.9 months with promising data anticipated to be updated in 2026. While the combination treatment was reported as well-tolerated, the study also noted the emergence of immune-related gastritis in some patients, indicating potential safety considerations.

Dec 30, 2025

NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026

NovaBridge Biosciences will ring the Nasdaq Opening Bell on January 2, 2026, celebrating its inclusion in the Nasdaq Biotech Index. This event highlights the company's transition to a global biotech platform and its commitment to innovative therapies. The leadership emphasizes their strategic vision and the potential for shareholder value in the coming year.

Dec 11, 2025

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

NovaBridge Biosciences presented positive Phase 1 dose expansion data for ragistomig at ESMO-IO 2025. The new dosing schedule of 3mg/kg every six weeks demonstrated consistent antitumor activity and improved safety compared to the previous schedule. The results indicate potential for ragistomig in treating relapsed/refractory solid tumors, supporting its advancement into combination studies.

Dec 11, 2025

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have...

NovaBridge Biosciences presented promising Phase 1 data for ragistomig, a bispecific antibody targeting advanced solid tumors, at ESMO-IO 2025. The new Q6W dosing schedule showed comparable anti-tumor efficacy to the previous Q2W regimen, with a significantly improved safety profile. The data suggest a favorable immune response and support the advancement of ragistomig into combination studies.

Dec 4, 2025

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO • Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibit

NovaBridge announced that the expanded Phase 1 data for ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, will be presented at ESMO-IO on December 10, 2025. The study demonstrated strong anti-tumor efficacy while improving the safety profile, particularly hepatic safety. These findings are crucial as ragistomig aims to offer new treatment options for patients resistant to current checkpoint inhibitors and potentially advance clinical development into combination studies.

Dec 4, 2025

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a...

NovaBridge Biosciences announced that expanded Phase 1 data for ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, will be presented at ESMO-IO 2025. The study demonstrated strong anti-tumor efficacy and an improved safety profile with a new dosing schedule. The interim results will be shared in a poster session, highlighting the potential for further clinical development.

Nov 21, 2025

NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable...

NovaBridge's subsidiary, Visara, has appointed Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Chair of the Scientific Advisory Board. Their expertise is expected to drive the development of VIS-101, a bifunctional biologic targeting VEGF-A and ANG-2, which aims to address wet AMD, DME, and RVO. The program is anticipated to be Phase-3-ready by 2026.

NovaBridge Biosciences Supplemental and Updated Disclosures NovaBridge Biosciences (the "Company" or "we") has filed an application (the "Listing Application") with the Stock Exchange of Hong King Limited (the "Hong Kong

NovaBridge Biosciences has filed a Listing Application for a dual primary listing of its shares on the Hong Kong Stock Exchange, coupled with an initial public offering. This filing includes supplemental disclosures about the company’s business and financial status. The company is also advancing a new business model focused on high-value therapeutic assets through strategic partnerships. However, uncertainties regarding the timing of the listing and risks related to clinical development were noted in the disclosures.

Oct 30, 2025

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective

NovaBridge Biosciences has officially transitioned from I-MAB, following shareholder approval, and will trade under the ticker NBP starting October 30, 2025. This rebranding aligns with the company’s strategy to become a global biotech platform, enhancing access to innovative medicines. A dual listing on Nasdaq and the Hong Kong Stock Exchange is planned, aimed at improving capital access and investor engagement. The company continues to advance its clinical pipeline, particularly focusing on promising therapies like givastomig and VIS-101, which are positioned to address significant medical needs.

Oct 30, 2025

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for ...

NovaBridge's subsidiary, Visara, has assigned its exclusive license for VIS-101 to Everest Medicines, aiming to expedite its development in Greater China and other Asian markets. VIS-101 is a bifunctional biologic targeting VEGF-A and ANG-2, with expectations to be Phase-3-ready by 2026. The partnership leverages Everest's clinical and commercialization expertise.

Oct 29, 2025

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries • NovaBridge subsidiary Visara assigned its exclusive license to Evere

NovaBridge's subsidiary Visara has assigned its exclusive license for VIS-101 to Everest Medicines, aiming to enhance its development for wet AMD in Greater China and other Asian markets. The collaboration is expected to leverage Everest's clinical and commercialization expertise, potentially bringing VIS-101 to patients more swiftly. Ian Woo's appointment to the NovaBridge board is also seen as a strategic advantage, given his significant background in biopharma finance and management. VIS-101 is currently completing a Phase 2 study and is on track to enter Phase 3 in 2026.

Oct 29, 2025

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide ...

NovaBridge Biosciences, formerly I-MAB, has announced its rebranding and strategic transformation to enhance its global biotech platform. The company plans to pursue a dual listing on Nasdaq and the Hong Kong Stock Exchange while advancing its clinical pipeline, including the promising drug givastomig. The new brand reflects a commitment to innovative therapies and improved patient access.

Oct 24, 2025

Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC) Samuel

The article reports updated results from a Phase I study of Givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB, in patients with advanced gastroesophageal carcinoma. Givastomig was found to be well tolerated, with encouraging activity observed in heavily pretreated patients. After additional follow-up, the data showed a sustained objective response rate of 18% without any dose-limiting toxicities. However, a notable percentage of patients experienced severe adverse events, raising concerns regarding safety and the need for careful monitoring.

Oct 23, 2025

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on

I-Mab is presenting updated positive data on its bispecific antibody, givastomig, targeting Claudin 18.2 in metastatic gastric cancer at the 2025 AACR-NCI-EORTC conference. The Phase 1 study reports an 18% objective response rate among heavily pre-treated patients, along with favorable safety data across various dosage levels. The company plans to advance its clinical strategy in first-line gastric cancer, with topline results expected in Q1 2026 for the combination studies. Givastomig's findings suggest its potential as a leading therapy in a market projected to be worth $2 billion.

Oct 16, 2025

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences • New business model reflects strategic transition to a gl

I-Mab, soon to rebrand as NovaBridge Biosciences, has announced a strategic transformation aimed at creating a global biotech platform. The company intends to pursue a dual listing on NASDAQ and the Hong Kong Stock Exchange through an initial public offering. Additionally, I-Mab has plans to acquire VIS-101, a bifunctional biologic targeting specific ocular conditions, expected to enhance patient treatment options. This transition will be supported by the expertise of newly appointed CFO Kyler Lei, aiming to broaden investor access and capitalize on opportunities in the Asia Pacific biopharma sector.

Sep 24, 2025

I-Mab 天境生物 2440 Research Boulevard, Suite 400 Rockville, MD 20850 PROXY STATEMENT General The board of directors of I-Mab (the “ Company ”), a Cayman Islands exempted company wit

I-Mab is soliciting proxies for its extraordinary general meeting set for October 24, 2025, focusing on the approval of a name change to NovaBridge Biosciences and the adoption of new corporate governance documents. Shareholders on record as of September 12, 2025, are entitled to vote on the proposals. The meeting will be held in Washington, D.C., and all relevant materials are available to shareholders for review ahead of time.

Sep 8, 2025

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments • Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in co

I-Mab has announced the acceleration of its investment in givastomig, an investigational bispecific antibody targeting Claudin 18.2. The company plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy in Q1 2026, following promising Phase 1b trial data. Additionally, I-Mab will explore expanding the use of givastomig into other Claudin 18.2-positive gastrointestinal cancers. Leadership changes were also made, with Mr. Wei Fu appointed as Executive Chairman.

Aug 25, 2025

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee • Dr. Robert Lenz, Ms. Xin Liu

I-Mab has announced the appointment of several seasoned biotech executives, including Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao, to its Board of Directors as part of a strategic move to support its growth. The formation of a Research and Development Committee, chaired by Dr. Lenz, is aimed at accelerating the company's innovation initiatives. Additionally, Dr. Ken Takeshita has been appointed to the Scientific Advisory Board to further enhance the company's focus on immuno-oncology advancements.

Aug 20, 2025

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update • Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers prese

I-Mab reported positive Phase 1b dose escalation results for givastomig, showing an 83% objective response rate when combined with immunochemotherapy for first-line gastric cancer patients. The company announced its strengthened cash position post an underwritten offering, which is expected to fund operations through late 2028. Upcoming milestones include topline data from the dose expansion study anticipated in Q1 2026. Overall, these developments indicate a promising trajectory for I-Mab's pipeline in immuno-oncology.

Aug 11, 2025

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers • Enrollment in the planned second dose expansion cohor

I-Mab has successfully completed enrollment for its Phase 1b dose expansion study of givastomig in combination with nivolumab and mFOLFOX6 for patients with 1L gastric cancers. The study, which involved 40 patients, is designed to assess the safety and efficacy of this bispecific antibody targeting Claudin 18.2. Preliminary results from earlier cohorts were positive, showing an 83% objective response rate. Topline results are anticipated in Q1 2026, indicating potential for substantial advancements in gastric cancer treatment.

Aug 1, 2025

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares ROCKVILLE, MD

I-Mab announced the pricing of an underwritten offering of American Depositary Shares (ADSs) amounting to $65 million. The offering includes 33,333,334 ADSs at an offering price of $1.95 each and is expected to close on August 5, 2025. The proceeds from this offering will fund the clinical development of the bispecific antibody, givastomig, aimed at treating Claudin 18.2-positive gastric cancers. The offering has garnered participation from both new and existing investors.

Jul 17, 2025

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health • Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-spe

I-Mab has acquired Bridge Health Biotech, gaining upstream rights to the CLDN18.2 parental antibody for use in bispecific applications. This strategic acquisition aims to strengthen the development of I-Mab’s lead candidate, givastomig, which targets Claudin 18.2-positive tumors. The agreement includes a $1.8 million upfront payment with potential future milestone payments contingent on development success. Recent clinical data indicates promising efficacy for givastomig in treating gastric cancer, with topline results expected in early 2026.

Jul 2, 2025

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 Data show confirmed ORR of 83% (10/12) at doses selected for ong

I-Mab announced positive results from a Phase 1b study of givastomig, a bispecific antibody, in combination with nivolumab and chemotherapy for treating gastric cancer. The study reported an impressive confirmed objective response rate (ORR) of 83% at selected doses for further expansion. Overall, the treatment showed good tolerability with minimal severe side effects. The findings were presented at the ESMO GI 2025 conference, enhancing confidence in the drug's potential for broader applications in gastric cancer treatment.

Jun 26, 2025

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 71% objective response rate (ORR) (12/17) per RECIST v1.1, wit

I-Mab has announced positive results from its Phase 1b dose escalation study of givastomig in combination with nivolumab and mFOLFOX6 for patients with first-line metastatic gastric cancers. The study reported a 71% objective response rate (ORR) and a favorable safety profile. Notably, the drug demonstrated efficacy in patients with low PD-L1 and/or Claudin 18.2 expression. I-Mab plans to present these findings at the ESMO GI 2025 conference on July 2nd and will host an investor event shortly thereafter.

Jun 12, 2025

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement ROCKVILLE, MD

I-Mab has announced that it has regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price of $1.00 for 10 consecutive business days. Nasdaq has confirmed that this requirement is now fulfilled, allowing I-Mab's American Depositary Shares to remain listed. The company is focused on developing precision immuno-oncology agents, particularly its lead candidate, givastomig, aimed at treating Claudin 18.2-positive gastric cancers.

Jun 2, 2025

Transforming Potential into Reality I-Mab Biopharma June 2025 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information inc

I-Mab Biopharma is advancing its drug candidate Givastomig, a bispecific antibody targeting CLDN18.2, with promising clinical data and significant market potential in gastric cancer. The company has fully enrolled its Phase 1b escalation study and is set to present topline data at the ESMO GI 2025 conference. I-Mab has a solid financial position, with cash reserves projected to support operations through major clinical milestones. The therapeutic landscape for gastric cancer remains challenging, yet Givastomig aims to improve outcomes for a significant patient population.

May 15, 2025

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update • Prioritization of givastomig as I-Mab's lead program positions the Company for clinical progress • New givastomig combinatio

I-Mab (NASDAQ: NBP) reported its first quarter 2025 financial results, emphasizing the progress of its lead program, givastomig. With a robust cash position of $168.6 million, the company is poised for clinical advancements, particularly in gastric cancers. Enrollment for the Phase 1b study has been expedited, and key data presentations are anticipated at upcoming conferences, including ESMO GI. The company noted a net loss improvement, reflecting better operational efficiencies and strategic focus.

Apr 30, 2025

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025 The ESMO Gastrointestinal Cancers Congress to be held July 2-5 in Barcelona ROCKVILLE, MD

I-Mab announced the acceptance of an abstract for its drug givastomig for an oral presentation at the ESMO Gastrointestinal Cancers Congress 2025. The drug, designed for treating CLDN18.2-positive metastatic gastric cancers, has shown promising results in Phase 1 trials and is undergoing further evaluation in combination with nivolumab and chemotherapy. The presentation at ESMO GI aims to highlight the efficacy of this promising therapy as I-Mab continues to build on positive early data. The study's enrollment has been proceeding well, indicating strong interest in the treatment being developed.

Apr 4, 2025

Transforming Potential into Reality I-Mab Biopharma April 2025 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information in

I-Mab Biopharma is focusing on its pipeline and capital strategy to enhance its precision immuno-oncology initiatives. The company has several drug candidates in various development phases, with Givastomig leading the charge due to its potential as a best-in-class therapy for gastric cancer. Despite the promising outlook, the company acknowledges the substantial risks and uncertainties surrounding regulatory approvals and the need for independent verification of its market assumptions. I-Mab has implemented a disciplined capital approach and plans to maintain a strong operational framework as it embarks on clinical trials.

Apr 3, 2025

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update • Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n

I-Mab reported its financial results for the full year 2024, highlighting a positive trajectory in the Phase 1b combination trial of givastomig for first-line gastric cancer. The company has completed enrollment in the first dose expansion cohort ahead of schedule and maintains a robust cash position expected to sustain operations through 2027. While the company has divested its Greater China assets, it continues to face challenges, such as ongoing legal disputes and reporting a net loss from continuing operations.

Mar 21, 2025

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement ROCKVILLE, MD

I-Mab has received a notice from Nasdaq indicating it does not meet the minimum bid price requirement of $1.00 per American Depositary Share (ADS). The company has 180 days, until September 15, 2025, to regain compliance by maintaining a bid price at or above the minimum for ten consecutive business days. While the receipt of the notice does not impact trading or reporting requirements, failure to comply could lead to delisting from the exchange. I-Mab is actively evaluating options to address this issue.

Mar 7, 2025

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress • Enrollment completed ahead of schedule in the first dose expansion cohort • Momentum continues with first patient dosed in the second expansi

I-Mab has reported significant progress in its Phase 1b study of givastomig, an innovative bispecific antibody targeting gastric cancer. Enrollment for the first dose expansion cohort has been completed ahead of schedule, while the first patient has been dosed in the second cohort. The company anticipates releasing topline data from the 40-patient dose expansion study in the first half of 2026, with encouraging early data about the drug's efficacy and tolerability. Future presentations are planned for both the dose escalation and expansion data, highlighting I-Mab's commitment to advancing its clinical pipeline.

Feb 27, 2025

Transforming Potential into Reality I-Mab Biopharma February 2025 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information

I-Mab Biopharma provided an update on its clinical programs, highlighting the company's pipeline that includes Givastomig, uliledlimab, and ragistomig. Givastomig, a bispecific antibody targeting Claudin 18.2, has shown initial signs of efficacy in gastric cancer treatment. However, the company faces multiple challenges including establishing the safety of its drug candidates and obtaining regulatory approvals. The update also emphasizes I-Mab's strategic focus on precision immuno-oncology therapeutics.

Jan 13, 2025

Transforming Potential into Reality I-Mab Biopharma January 2025 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information

I-Mab Biopharma is showcasing its pipeline developments in immuno-oncology, particularly focusing on its lead asset, Givastomig, targeting CLDN18.2 in gastric cancer. The company is advancing three clinical programs and has shared projections for upcoming data milestones. While optimistic about its potential market opportunities, the presentation also acknowledges significant risks associated with the approval and commercialization of its drug candidates. Furthermore, I-Mab emphasizes a disciplined capital approach following its divestiture of China operations in 2024.

Jan 8, 2025

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Deposit

I-Mab has announced that its Chairman, Wei Fu, intends to purchase up to $2,000,000 of the company's American Depositary Shares in open market transactions. This move signals confidence in the company's strategic direction and the promising potential of its lead clinical program, givastomig. The timing and extent of these purchases remain uncertain, as they will be executed through a controlled entity. Meanwhile, I-Mab's cash runway is expected to last until 2027, supporting continued development efforts.

Jan 6, 2025

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program • Givastomig: a Claudin 18.2 (“CLDN18.2”) x 4-1BB bispecific antibody, will be t

I-Mab has announced the prioritization of its bispecific antibody, givastomig, as its lead clinical program. This decision follows the completion of a dose escalation study and a current dose expansion study aiming to gather more data by early 2026. I-Mab's financial status remains strong with $184.4 million in cash expected to fund operations until 2027. The company also noted a pause in the development of uliledlimab to shift resources to givastomig, while it continues to monitor promising data from related studies.

Dec 3, 2024

Transforming Potential into Reality I-Mab Biopharma

I-Mab Biopharma has undergone significant organizational changes, including the completion of their China operations divestiture and a shift towards a US-based leadership team. The company has laid out a clinical strategy aimed at advancing its pipeline, which includes drug candidates targeting major cancers. However, I-Mab also faces numerous challenges, such as proving the safety and efficacy of its candidates and obtaining necessary regulatory approvals.

Nov 6, 2024

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer ROCKVILLE, MD

I-Mab has appointed Sean Fu, PhD, MBA, as its permanent Chief Executive Officer effective November 1, 2024, after serving as Interim CEO since July 2024. Fu's leadership is expected to further I-Mab's mission to develop innovative cancer immunotherapies. With over 20 years in the life sciences field, Fu aims to advance the company's clinical programs and collaborate with the Board and team. His past experiences include significant roles at prominent pharma companies, showcasing his capability in biopharmaceutical development.

Nov 1, 2024

I-Mab Reports Third Quarter 2024 Results • Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data • On track to dose first patient in randomized Phase 2 study of uliled

I-Mab announced its third quarter 2024 results, highlighting encouraging data for its Givastomig therapy at ESMO 2024 and the plan to dose the first patient in a randomized Phase 2 study of uliledlimab in first-line metastatic non-small cell lung cancer in 2025. The company appointed Dr. Sean Fu as permanent CEO, indicating a stable leadership transition. Financially, I-Mab retains a strong cash position, estimated to last into 2027, which will support ongoing R&D efforts amidst decreased cash reserves and ongoing arbitration related to its China operations.

Sep 16, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 - Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily

I-Mab has presented promising data from an ongoing Phase 1 clinical study of givastomig, a bispecific antibody targeting Claudin 18.2 in gastric cancer patients, at ESMO 2024. The study showed encouraging single-agent activity, with partial responses observed in 16.3% of patients and a favorable safety profile. A Phase 1b study is ongoing to evaluate givastomig in combination with nivolumab and chemotherapy for front-line treatment. The findings suggest that givastomig has the potential to be a differentiated therapeutic option for gastric cancer.

Aug 28, 2024

SECONDMENT AGREEMENT THIS SECONDMENT AGREEMENT (the “ Agreement ”) is made effective as of

I-MAB Biopharma US Limited has entered into a secondment agreement with ABio-X Holdings, Inc., whereby Sean Xi-Yong Fu will serve as interim CEO for six months starting from July 15, 2024. This collaboration entails that while employed by ABio-X, Fu will contribute full-time leadership services to I-MAB. The agreement stipulates that ABio-X will receive monthly fees for Fu's services, while maintaining his salary and benefits through ABio-X. The arrangement emphasizes confidentiality and the handling of proprietary work, although it does carry the risk of instability due to the interim nature of Fu's role.

Aug 28, 2024

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates • Completed divestiture of China operations • Uliledlimab IND clearance paves the way for U.S. combination studies in first-l

I-Mab reported its financial results for the first half of 2024, highlighting significant pipeline developments and a completed divestiture of its operations in China. Key advancements include the IND clearance for uliledlimab and collaborations for givastomig with Bristol Myers Squibb. The company remains financially robust with $207.5 million in cash, sufficient to drive its oncology programs forward. The presentation of early clinical data at ASCO 2024 showcases encouraging responses from its bispecific antibodies.

Aug 7, 2024

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKV

I-Mab has appointed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm for the fiscal year ending December 31, 2024. This decision is part of the company's strategic transition to becoming a fully U.S.-based biotech organization. I-Mab's management believes that this appointment will enhance compliance with audit requirements and align with shareholders' long-term interests. The transition was performed without any disagreements or unresolved matters with the previous auditor and is expected to facilitate further growth and corporate governance improvements.

Jul 15, 2024

I-Mab Announces Leadership Transitions ROCKVILLE, MD

I-Mab announced significant leadership changes, appointing Mr. Wei Fu as the new Chairman and Dr. Sean Xi-Yong Fu as Interim CEO. Mr. Raj Kannan will step down but remain as an advisor until the end of July 2024. These transitions will further I-Mab's objectives for scientific innovation and the advancement of its immunotherapy pipeline. The company is poised for a strategic transformation into a U.S.-based biotech firm, focused on delivering new treatment options for patients globally.

Jun 5, 2024

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers I-Mab enters clinical collaboration with Bristol Myers Squibb to ev

I-Mab has announced a clinical trial collaboration with Bristol Myers Squibb to evaluate the investigational bispecific antibody givastomig in combination with nivolumab and chemotherapy for treating newly diagnosed advanced gastric and esophageal cancers. This multinational Phase 1 study will investigate the potential of givastomig, which has previously shown promising single-agent activity, in a triple therapy approach. Collaborative efforts will leverage Bristol Myers Squibb's immune checkpoint inhibitor to enhance therapeutic effects. The study signifies I-Mab's commitment to advancing novel immunotherapies in oncology.

May 23, 2024

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response

I-Mab announced positive Phase 1 clinical data for its bispecific antibody ragistomig at ASCO 2024. The data revealed a 25% objective response rate and 75% clinical benefit rate in heavily pre-treated patients with advanced solid tumors. The study met its primary endpoints and demonstrated manageable safety and dose proportional pharmacokinetics. The findings support further development of ragistomig both as a monotherapy and in combination with other therapies.

Apr 2, 2024

I-Mab Announces Closing of the Divestiture of Business Operations in China ROCKVILLE, MD

I-Mab has successfully closed the divestiture of its business operations in China by transferring 100% of its outstanding equity interest in I-Mab Biopharma Co., Ltd. to I-Mab Biopharma (Hangzhou) Co., Ltd. The transaction, previously announced in February 2024, could yield an aggregate consideration of up to US$80 million, contingent on the achievement of future milestones. Concurrently, I-Mab Hong Kong extinguished US$183 million in repurchase obligations to certain shareholders. Additionally, I-Mab participated in a Series C fundraising for the Hangzhou Company with US$19 million.

Mar 15, 2024

I-Mab Reports Full Year 2023 Financial Results and Business Update Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected

I-Mab reported its full year 2023 financial results highlighting significant clinical progress with its lead assets uliledlimab and givastomig. The company announced a strategic agreement to divest its operations in China, which is anticipated to relieve future development costs and improve its financial positioning. Despite a reported net revenue of RMB27.6 million, I-Mab faces challenges, including a goodwill impairment reflecting an ongoing disconnect between expected future performance and current realities.

Feb 7, 2024

I-Mab Signs Agreement to Divest its Assets and Business Operations in China Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech Agreement provides for a strategic focus i

I-Mab announced a strategic divestiture of its assets and operations in China as part of its transition to a U.S.-based biotech company. The definitive agreements involve transferring ownership of its Chinese subsidiary for up to $80 million, depending on future milestones. Alongside this transaction, I-Mab will undergo management changes, appointing Pamela Klein as Interim Chairperson. The company aims to reduce operational costs while strengthening its portfolio for potential new opportunities outside Greater China.

Oct 10, 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 - Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial respo

I-Mab and ABL Bio have reported promising updates on their PD-L1 and 4-1BB bispecific antibody TJ-L14B/ABL503 in a Phase 1 study. Among 14 efficacy-evaluable patients, one achieved a complete response while another had a partial response. The treatment is specifically targeting tumors resistant to PD-(L)1 antibodies. The company plans to present further clinical data at a major conference in early 2024.

Aug 17, 2023

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates Significant progress made year-to-date on key clinical assets: - Uliledlimab (CD73 antibody): Encouraging early results were presented at ASC

I-Mab has released its mid-year financial results for 2023, highlighting significant progress in its clinical asset pipeline. Key achievements include promising early results for uliledlimab and givastomig, alongside positive Phase 3 outcomes for eftansomatropin alfa. The company emphasizes its strategic focus on advancing oncology programs while maintaining a healthy balance sheet. Additionally, it plans to file a Biologics License Application (BLA) for eftansomatropin alfa in China in 2024.

Jun 22, 2023

I-Mab Announces the Appointment of Raj Kannan as CEO GAITHERSBURG, MD. and SHANGHAI, CHINA

I-Mab announced the appointment of Raj Kannan as its new CEO, effective June 22, 2023. Kannan, who has over 30 years of experience in the biotech industry, is expected to strengthen the company's strategic position and enhance its oncology portfolio. The company has over 10 clinical and pre-clinical stage drug candidates and aims to bring transformational medicines to patients globally. Dr. Andrew Zhu, the acting CEO prior to Kannan's appointment, will continue to lead I-Mab's R&D efforts.

May 25, 2023

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Uliledlimab is a differentiated monoclonal antibody designed t

I-Mab has reported encouraging Phase 1b/2 study results for its combination therapy of Uliledlimab and Toripalimab in patients with advanced NSCLC. The study showed a favorable safety profile and a 31.3% objective response rate overall, which increased significantly for patients with high CD73 expression. The company is optimistic about the implications of these findings and plans to initiate further trials, focusing on CD73 as a predictive biomarker for treatment response. The full results will be shared at the ASCO Annual Meeting in June 2023.

May 1, 2023

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended

I-Mab reported its financial results for the year ended December 31, 2022, highlighting progress on key clinical assets amidst macroeconomic challenges. The company has successfully repositioned its business strategy to streamline operations and reduce cash burn. Significant achievements include positive Phase 2 data for lemzoparlimab and uliledlimab, with plans for a Phase 3 trial in China. Strategic partnerships, particularly with Jumpcan for the commercialization of eftansomatropin alfa, enhance growth prospects in the upcoming years.

Apr 25, 2023

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon - Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute - Tribunal complete

I-Mab announced a positive outcome in arbitration with Tracon Pharmaceuticals regarding two collaboration agreements. The arbitration awarded I-Mab the termination of the TJD5 Agreement and denied Tracon's over $200 million breach claim under the BsAb Agreement. With these disputes resolved, I-Mab plans to expedite the clinical development and global partnerships for its proprietary antibody assets, further enhancing its business prospects. This ruling marks a significant victory for I-Mab and its shareholders.

Apr 24, 2023

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China GAITHERSBURG, MD. and

I-Mab has announced the successful dosing of the first patient in a Phase 3 registrational trial for its CD47 antibody, lemzoparlimab, aimed at patients with higher-risk myelodysplastic syndrome (MDS) in China. This trial is significant as it marks the first approved Phase 3 trial for anti-CD47 therapies in mainland China, with lemzoparlimab being tested in combination with azacitidine. The company is optimistic that this treatment could address the unmet medical needs of MDS patients who currently have very limited options. The trial's outcome could potentially establish lemzoparlimab as the first-to-market CD47-targeting therapy in China.

Nov 10, 2022

I-Mab INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended

1688271901888573531888573536.385.540.8314.6712.741.901688271901888573531888573536.385.540.831838267531911273362.311223000001741000000 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2021

Sep 10, 2022

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 Lemzoparlimab combined with AZA showed encouraging clinical

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome - Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients - For patients received initia

Aug 30, 2022

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended

Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 will host conference calls and webcasts on August 30, 2022. A Mandarin session will be held at 7:00 a.m. ET and an English session will be held at 8:15 a.m. ET. Md. and

May 26, 2022

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab - Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting t

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab SHANGHAI, China and GAITHERSBURG, MD., May 26, 2022 - I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commer

May 5, 2022

I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act SHANGHAI and GAITHERSBURG, MD.

I-Mab Provides Updates on Status under Holding Foreign Companies SHANGHAI and GAITHERSBURG, MD. May 5, 2022 I-Mab ( I-Mab or the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologic

Apr 28, 2022

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global allianc

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer SHANGHAI, China and GAITHERSBURG, MD. April 28, 2022 I-Mab ( I-Mab or the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the dis

Mar 31, 2022

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment SHANGHAI and GAITHERSBURG, MD.

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment SHANGHAI and GAITHERSBURG, MD. March 31, 2022 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and comme

Mar 3, 2022

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer SHANGHAI, China and GAITHERSBURG, MD.

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer SHANGHAI, China and GAITHERSBURG, MD. March 3, 2022 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company c

Jan 28, 2022

I-Mab s Announcement on Unusual Price Movement SHANGHAI, China, and GAITHERSBURG, MD. I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercia

I-Mab s Announcement on Unusual Price Movement SHANGHAI, China, and GAITHERSBURG, MD. I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics. The Company has noted the rec

Dec 21, 2021

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization New appointments as part of the Company s strategic development plans to accelerate transf

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization SHANGHAI, China and GAITHERSBURG, MD. December 20, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed t

Dec 14, 2021

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 - Positive clinical activity was observed in heavily pretreated patients who

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 Positive clinical activity was observed in heavily pretreated patients who had progressed on prior Anti-CD20 therapies GAITHERSBURG,

Dec 7, 2021

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited SHANGHAI, China December 7, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of nove

Dec 3, 2021

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors SHANGHAI, CHINA, and GAITHERSBURG, MD.

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors SHANGHAI, CHINA, and GAITHERSBURG, MD. December 3, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmace

Nov 9, 2021

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity B

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC SHANGHAI, China, GAITHERSBURG, MD. and SEONGNAM, South Korea. November 9, 2021 I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, developmen

Nov 5, 2021

I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins s Lymphoma at ASH 2021 Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in c

I-Mab to Present Clinical Data of Lemzoparlimab in Combination in Non-Hodgkins s Lymphoma at ASH 2021 SHANGHAI, China and GAITHERSBURG, MD. November 4, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development

Nov 1, 2021

I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments - Industry veteran John Long appointed as CFO to lead I-Mab s global corporate finance and capital market a

I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments GAITHERSBURG, MD. November 1, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and com

Oct 18, 2021

I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China SHANGHAI, China and GAITHERSBURG, MD.

I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China SHANGHAI, China and GAITHERSBURG, MD. October 18, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discove

Oct 13, 2021

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for seco

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China SHANGHAI, China and GAITHERSBURG, MD., October 13, 2021 I-Mab (the Company ) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, developmen

Sep 30, 2021

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021 T

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab SHANGHAI, China and GAITHERSBURG, MD., September 30, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and

Aug 19, 2021

I-Mab Announces Establishment of Environmental, Social and Governance Committee I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI New majority independent ESG committee to set ove

I-Mab Announces Establishment of Environmental, Social and Governance Committee SHANGHAI, China and GAITHERSBURG, MD. August 19, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization o

Aug 11, 2021

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19 Interim analysis showed positive preliminary results for maintaining patients

I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19 SHANGHAI, China and GAITHERSBURG, MD. August 11, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company

Jul 29, 2021

I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million SHANGHAI and GAITHERSBURG, MD.

I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million SHANGHAI and GAITHERSBURG, MD. July 29, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer

Jul 27, 2021

I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange

I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange China July 27, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of

Jul 22, 2021

I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China - Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients i

I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China - Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase 1b/2 trial in South Korea in patients with GBM

Jun 25, 2021

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus SHANGHAI, China and GAITHERSBURG, MD.

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus SHANGHAI, China and GAITHERSBURG, MD., June 25, 2021- I-Mab (the Company ) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development an

May 18, 2021

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome The phase 2 combination trial could potentially

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome SHANGHAI, China and GAITHERSBURG, MD. May 18, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stag

Apr 26, 2021

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis SHANGHAI, China, and GAITHERSBURG, MD

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis SHANGHAI, China, and GAITHERSBURG, MD April 26, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat

Apr 6, 2021

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors SHANGHAI, China, GAITHERSBURG, MD, and SEONGNAM, South Korea

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors China, GAITHERSBURG, MD, and SEONGNAM, South Korea April 6, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biop

Mar 29, 2021

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates 18 significant clinical milestones achieved since the Company s IPO in January 2020, with multiple important data readouts for lemzoparl

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates SHANGHAI, China and GAITHERSBURG, Md., March 29, 2021 /GLOBE NEWSWIRE/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and

Feb 9, 2021

Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced SHANGHAI, China, and GAITHERSBURG, MD.

Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders SHANGHAI, China, and GAITHERSBURG, MD., February 9, 2021 a registered follow-on public offering by certain pre-IPO shareholders (the Selling Shareholders ) of 3,283,950 American de

Feb 5, 2021

Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab SHANGHAI, China, and GAITHERSBURG, MD.

Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of SHANGHAI, China, and GAITHERSBURG, MD., February 5, 2021 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, d

Feb 5, 2021

I-Mab INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements for the Nine Months Ended

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements for the Nine Months Ended September 30, 2019 and 2020 Page Consolidated Balance Sheet as of December 31, 2019 and Unaudited Interim Condensed Consolidated Balance Sheet a

Feb 5, 2021

I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S. - First patient dosed in a combination study with anti-PD1 in China - Topline results from U.S. phase 1

I-Mab Announces Multiple Clinical Advancements of its Antibody Uliledlimab in China and the U.S. - First patient dosed in a combination study with anti-PD1 in China - Topline results from U.S. phase 1 study demonstrate safety and clinical activity - Data from preclinical and

Nov 12, 2020

I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial SHANGHAI, China, and GAITHERSBURG, MD.

I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial SHANGHAI, China, and GAITHERSBURG, MD. November 12, 2020 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to t

Nov 11, 2020

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 Oral presentation highlights the unique epitope, pharmacological profile and anti-tumor properties of TJ210/MOR210 SHANGHAI,

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR TJ210/MOR210 at SITC 2020 Oral presentation highlights the unique epitope, pharmacological profile and anti-tumor properties of TJ210/MOR210 SHANGHAI, China, and GAITHERSBURG, MD. November 11, 2020 I-Mab (the Compan

Nov 9, 2020

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting - Initial monotherapy results demonstrate differentiated safety and PK profil

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting - Initial monotherapy results demonstrate differentiated safety and PK profile and efficacy signal of lemzoparlimab for the treatment

Oct 5, 2020

I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency - Eftansomatropin, a long acting recombinant human growth hormone (rhGH) ready

I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency - Eftansomatropin, a long acting recombinant human growth hormone (rhGH) ready for Phase 3 Clinical Trial in China SHANGHAI, China, and GAITHERS

Sep 21, 2020

I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma - First international multi-center clinical trial (IMCT) of lemzoparlimab in China - Second IND

I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma - First international multi-center clinical trial (IMCT) of lemzoparlimab in China - Second IND approval from China NMPA for lemzoparlimab SHANGHAI, C

Sep 17, 2020

MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer Phase 1 Clinical Study Expected to Start in Q4 2020 PLANEGG/MUNICH, Germany, and

MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer Phase 1 Clinical Study Expected to Start in Q4 2020 PLANEGG/MUNICH, Germany, and SHANGHAI, China, September 17, 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment,

Sep 4, 2020

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium Ordinary Share Purchase price equivalent to $33.00 per ADS, at a premium to the 30-day volume weighted average price ( VWAP ) Demonstra

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium Ordinary Share Purchase price equivalent to $33.00 per ADS, at a premium to the 30-day volume weighted average price ( VWAP ) leading biotech investors strong endorsement of I-Mab s R&D innova

Aug 31, 2020

I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and

I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global eff

Aug 17, 2020

I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China SHANGHAI and GAITHERSBERG, MD .

I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China SHANGHAI and GAITHERSBERG, MD. August 17, 2020 (PR Newswire) I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, develo

Aug 4, 2020

China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency SHANGHAI and GAITHERSBERG, MD.

China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth SHANGHAI and GAITHERSBERG, MD. August 4, 2020 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme

Jul 28, 2020

I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer SHANGHAI and GAITHERSBERG, MD.

I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer SHANGHAI and GAITHERSBERG, MD. July 28, 2020 (PR Newswire) I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, develop

Jul 15, 2020

I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million SHANGHAI, China and Gaithersburg, MD.

I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million SHANGHAI, China and Gaithersburg, MD., July 15, 2020 (PRNewswire) I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializ

Jun 12, 2020

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II SHANGHAI, China and Gaithersburg, MD.

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II Gaithersburg, MD., June 12, 2020 (PRNewswire) I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical com

May 28, 2020

I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with -Cytokine Release Syndrome - Though blinded, there is a trend for correlation between clinical improvement and

I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with -Cytokine Release Syndrome SHANGHAI, China and GAITHERSBURG, MD., May 28, 2020 /PRNewswire/ I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company committed t

May 21, 2020

I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7 in Glioblastoma Multiforme - I-Mab to initiate Phase 2 clinical trial in glioblastoma multiforme (GBM) in China - I-Mab and

I-Mab and Genexine Announce China NMPA Clearance for Phase TJ107/HyLeukin-7 in Glioblastoma - I-Mab to initiate Phase 2 clinical trial in glioblastoma multiforme (GBM) in - I-Mab and Genexine expand collaboration for development GAITHERSBURG, MD, and SEOUL, South Korea, May 2

May 13, 2020

First Patient Dosed with I-Mab s CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors SHANGHAI, China, and ROCKVILLE, MD.

First Patient Dosed with I-Mab s CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors SHANGHAI, China, and ROCKVILLE, MD., May 13, 2020 I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and co

Apr 27, 2020

I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China SHANGHAI, China, and ROCKVILLE, MD., and Munich, Germany

I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China SHANGHAI, China, and ROCKVILLE, MD., and Munich, Germany, April 27, 2020 (GLOBE NEWSWIRE) I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceuti

Apr 8, 2020

April 2020 I-MAB Presentation Disclaimer This presentation has been prepared by I-Mab (the "Company") solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowl

Disclaimer This presentation has been prepared by I-Mab (the "Company") solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied,

Apr 3, 2020

I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19) SHANGHAI, China and ROCKVILLE, MD.

I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19) SHANGHAI, China and ROCKVILLE, MD., April 3, 2020 I-Mab (Nasdaq: IMAB) ( the Company ), a clinical stage biopharmaceutical company

Apr 2, 2020

I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China - The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refracto

I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, SHANGHAI, China, and ROCKVILLE, MD., April 2, 2020 I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati

Mar 31, 2020

I-Mab Announces Financial Results for the Full Year Ended

I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Successfully completed initial public offering raising approximately $114.5 million in gross proceeds Continued execution across broad pipeline portfolio; multiple clinical data readouts e

Mar 30, 2020

I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology - Kalbe Genexine Biologics ( KG Bio ) will receive right of first ne

I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for Immuno-Oncology - Kalbe Genexine Biologics ( KG Bio ) will receive right of first negotiation for an exclusive license to potentially commerci

Mar 27, 2020

I-Mab Expands Global Out-Licensing and Business Development Efforts Fernando J. Sall s, Ph.D., CLP , Appointed to Lead I-Mab s U.S. and EU Business Development SHANGHAI, China and ROCKVILLE, MD.

I-Mab Expands Global Out-Licensing and Business Development Fernando J. Sall s, Ph.D., CLP , Appointed to Lead I-Mab s U.S. and EU Business Development SHANGHAI, China and ROCKVILLE, MD., March 27, 2020 (GLOBE NEWSWIRE) I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage bio

Mar 23, 2020

I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications SHANGHAI, China and ROCKVILLE, MD.

I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications SHANGHAI, China and ROCKVILLE, MD., -- March 23, 2020 -- (GLOBE NEWSWIRE) I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, developme

Mar 13, 2020

I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19) -The clinical study will explore the potential of TJ

I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease -The clinical study will explore the potential of TJM2, a proprietary mAb against GM-CSF, to fight cytokine storm during

Feb 10, 2020